RNXT_OUT_1 [2025-04-14 16:06:02 -0400] 3106 Bytes | 796 tokens | Cum: 796 tkns (9.95% of 8k)
==========================================================================

Listen up, partner—it's 4:06:01 PM on Mon Apr 14, 2025 -0400, and I’m revved up about RenovoRx (RNXT), climbing from 0.7720 to 0.8448. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

--- COMPANY PROFILE ---
Company: RenovoRx (RNXT)
IPO: 2021-08-26 (3 Years Ago)
Market Cap: $30,333,804
Shares Outstanding: 36,550,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Here’s the first list of news for RenovoRx:

C1 - Apr-04-25 08:30AM - RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10th
C2 - Apr-01-25 08:30AM - RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
C3 - Mar-28-25 08:00AM - RenovoRx Highlights New Human Pharmacokinetic Data Abstract at SSO 2025 Annual Meeting
C4 - Mar-26-25 08:00AM - RenovoRx Pre-Clinical Results Supporting TAMP as a Targeted Locoregional Drug Delivery Platform to Receive Award at SIR 2025 Annual Scientific Meeting
C5 - Mar-20-25 08:00AM - RenovoRx CEO to Provide Strategic Update During Fireside Chat on Thursday, April 3rd at 12:00 p.m. ET
C6 - Mar-19-25 08:00AM - RenovoRx Announces Abstract Presentation at the Society of Surgical Oncology (SSO) 2025
C7 - Feb-26-25 08:00AM - RenovoRx Advances Commercialization of RenovoCath with Several New Purchase Orders, Including Customer Reorders
C8 - Feb-13-25 08:00AM - RenovoRx Highlights Promising Pre-Clinical Data Abstract: TAMP Therapy Platform Offers Potential to Improve Localized and Targeted Drug Delivery

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and report parser.
Your role is to examine all available company data and draw sound conclusions.
The company under analysis is: RenovoRx (RNXT).

2) To request information, refer to any listed documents using their reference codes.

3) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs:

Restrict all your responses to just 3 tokes until it's time for the summary and data pairs at the end.
Request a document with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

RNXT_OUT_3 [2025-04-14 16:06:06 -0400] 579 Bytes | 176 tokens | Cum: 975 tkns (12.19% of 8k)
==========================================================================

Showing C2 (chunk 1 of 1): C2:
**RenovoRx Reports Initial Revenues from RenovoCath Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial**
Date: Apr-01-25 08:30AM
Source: (Business Wire)
URL: https://www.businesswire.com/news/home/20250401356598/en

Error fetching article: 403 Client Error: Forbidden for url: https://www.businesswire.com/news/home/20250401356598/en

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_5 [2025-04-14 16:06:07 -0400] 948 Bytes | 289 tokens | Cum: 1374 tkns (17.18% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-11T10:00:38Z - RenovoRx, Inc. (NASDAQ:RNXT) Director Laurence Marton Purchases 12,050 Shares...
A2 - 2025-04-10T23:04:05Z - RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com...
A3 - 2025-04-10T23:03:37Z - RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com...
A4 - 2025-04-10T23:04:06Z - RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com...
A5 - 2025-04-10T23:04:05Z - RenovoRx VP controller Ronald Kocak acquires over $10,000 in stock By Investing.com...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

RNXT_OUT_7 [2025-04-14 16:06:07 -0400] 1098 Bytes | 318 tokens | Cum: 1694 tkns (21.18% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**RenovoRx, Inc. (NASDAQ:RNXT) Director Laurence Marton Purchases 12,050 Shares**Date: 2025-04-11Source: {'uri': 'insidertrades.com', 'dataType': 'news', 'title': 'InsiderTrades.com'}URL: https://www.insidertrades.com/alerts/nasdaq-rnxt-insider-buying-and-selling-2025-04-11/RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) Director Laurence Marton acquired 12,050 shares of the company's stock in a transaction on Tuesday, April 8th. The shares were purchased at an average cost of $0.85 per share, with a total value of $10,242.50. Following the completion of the purchase, the director now directly owns 45,684 shares of the company's stock, valued at $38,831.40. This trade represents a 35.83 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of RNXT stock op

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_9 [2025-04-14 16:06:09 -0400] 1098 Bytes | 329 tokens | Cum: 2025 tkns (25.31% of 8k)
==========================================================================

Showing A1 (chunk 2 of 4): ened at $0.79 on Friday. The stock has a 50 day moving average price of $1.01 and a 200 day moving average price of $1.13. RenovoRx, Inc. has a 52-week low of $0.75 and a 52-week high of $1.69. The firm has a market capitalization of $18.98 million, a P/E ratio of -1.39 and a beta of 1.12.

RenovoRx (NASDAQ:RNXT - Get Free Report) last released its earnings results on Monday, March 31st. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.17 million. As a group, sell-side analysts forecast that RenovoRx, Inc. will post -0.4 EPS for the current year.

Separately, HC Wainwright reiterated a "buy" rating and set a $3.00 price target on shares of RenovoRx in a report on Friday, April 4th.

View Our Latest Report on RNXT

I

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_11 [2025-04-14 16:06:10 -0400] 1071 Bytes | 310 tokens | Cum: 2359 tkns (29.49% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-06-26T12:30:00Z - University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial
B2 - 2024-06-10T12:30:00Z - RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
B3 - 2024-01-02T18:35:24Z - Why Longboard Pharmaceuticals Shares Are Trading Higher By Around 200%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
B4 - 2023-12-28T18:07:18Z - Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B5 - 2023-06-30T10:00:00Z - What to Look for in a Penny Stocks Trading Platform 
B6 - 2023-06-29T17:52:35Z - Why Franklin Covey Shares Are Trading Higher By 25%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNXT_OUT_13 [2025-04-14 16:06:13 -0400] 750 Bytes | 223 tokens | Cum: 2584 tkns (32.30% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx’s Pivotal Phase III TIGeR-PaC Clinical Trial**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/06/26/2904496/0/en/University-of-Nebraska-Medical-Center-Launches-Patient-Enrollment-for-RenovoRx-s-Pivotal-Phase-III-TIGeR-PaC-Clinical-Trial.htmlOngoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer Ongoing Study is Investigating RenovoGem™ to treat Locally Advanced Pancreatic Cancer

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_15 [2025-04-14 16:06:13 -0400] 1091 Bytes | 289 tokens | Cum: 2925 tkns (36.56% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S8 - 2025-03-31 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis of our financial condition and results of operations for our fiscal year ended December 31, 2024 should be read in conjunction with the financial ...

S9 - 2025-02-10 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On February 6, 2025, RenovoRx, Inc., a Delaware corporation (the Company), entered into an underwriting agreement (the Underwriting Agrmt) by and between the Company and Titan Partners Group LLC, a division of American C...

S10 - 2024-11-14 8-K Item 2.02 Results of Oper and Fin Cond.

On November 14, 2024, RenovoRx, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2024. The full text of the press release is attached hereto as Exhibit 99.1 and is incorpor...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

RNXT_OUT_17 [2025-04-14 16:06:15 -0400] 1098 Bytes | 240 tokens | Cum: 3167 tkns (39.59% of 8k)
==========================================================================

Showing S8 (chunk 1 of 6): S8:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations for our fiscal year ended December 31, 2024 should be read in conjunction with the financial statements and related notes thereto included in Part II, Item 8, Financial Statements and Supplementary Data, of this Report. All information presented herein is based on our fiscal year. Unless otherwise stated, references to particular years, quarters, months or periods refer to our fiscal years ended December 31 and the associated quarters, months and periods of those fiscal years.

Some of the information contained in this discussion and analysis or set forth elsewhere in this Report, including information with respect to our plans and strategy for our business, includes forward-looking statements that i

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_19 [2025-04-14 16:06:20 -0400] 1098 Bytes | 250 tokens | Cum: 3439 tkns (42.99% of 8k)
==========================================================================

Showing S8 (chunk 2 of 6): nvolves risks and uncertainties. See Cautionary Note Regarding Forward-Looking Statements and Risk Factors for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements.

Unless the context otherwise requires, all references in this section to the Company, we, us, or our refer to RenovoRx, Inc.

Overview

We are a life sciences company offering RenovoCath , a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery system, targeting high unmet medical needs, with a present focus on difficult to treat cancers.

We are both a clinical stage and a commercial stage enterprise. As described further below, our lead product candidate, novel drug-device combination product (currently called IAG), is currently the subject of a Phase III clinical study for the treatment of

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_21 [2025-04-14 16:06:23 -0400] 1098 Bytes | 243 tokens | Cum: 3771 tkns (47.14% of 8k)
==========================================================================

Showing S8 (chunk 3 of 6): locally advanced pancreatic cancer (LAPC). At the same time, we are commercializing RenovoCath for standalone use by interventional radiologists, oncologists and other medical professionals who can use RenovoCath to treat patients within its FDA-cleared fields of use.

##TABLE_START 74 ##TABLE_END

IAG our RenovoCath device utilize our patented Trans-Arterial Micro-Perfusion ( TAMP) therapy platform, which is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapys toxicities versus systemic intravenous therapy, Including traditional chemotherapy. Our novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy. Our mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted therapeutic de

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_23 [2025-04-14 16:06:24 -0400] 1098 Bytes | 254 tokens | Cum: 4098 tkns (51.23% of 8k)
==========================================================================

Showing S8 (chunk 4 of 6): livery RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion.

For the past several years, we have focused our efforts on progressing IAG through clinical trials. However, based on organic demand from doctors in the field who have become familiar with our technology, in 2024, we made the decision to launch an effort to commercialize our RenovoCath delivery system as a standalone device within its FDA cleared uses. Commenced in the field in late 2024, this commercial effort has already begun to achieve positive results. To accommodate increased need for RenovoCath supply, we expanded our relationship with our U.S.-based third-party RenovoCath manufacturer. In December 2024, we announced that over ten medical institutions had initiated the process for RenovoCath purchase orders, and in Feb

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_25 [2025-04-14 16:06:25 -0400] 1098 Bytes | 247 tokens | Cum: 4366 tkns (54.57% of 8k)
==========================================================================

Showing S8 (chunk 5 of 6): ruary 2025, we announced additional purchase orders received from several esteemed, high volume National Cancer Institute-designated centers and that utilization of RenovoCath devices by our initial customers led to repeat purchase orders.

We have begun to generate and expect to grow revenue meaningfully from the sale of our RenovoCath devices. Importantly, we believe our current commercial strategy can be accomplished without a material increase in our capital expenditures, regardless of whether we self-commercialize or choose to partner with a larger organization with an existing sales force. Following our late 2024 commercial launch, we generated a small amount (approximately $43,000) of initial revenues from RenovoCath revenue in our fourth quarter ended December 31, 2024. We expect revenue to increase to the low six figure range for the first quarter ended March 31, 2025 followed

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

RNXT_OUT_27 [2025-04-14 16:06:34 -0400] 6585 Bytes | 1856 tokens | Cum: 6224 tkns (77.80% of 8k)
==========================================================================

This is our set of metrics for RenovoRx.
Please analyze the numbers.

+---------------------+-----------------------+------------------------+----------------------+
| Volume: 170,032 | Perf Month: -13.78% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+---------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 141.50K | Perf Quarter: -37.04% | Short Float: 0.75% | ROE: -1192.69% |
+---------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 1.23 | Index: - | Short Ratio: 1.86 | ROI: -187.93% |
+---------------------+-----------------------+------------------------+----------------------+
| RSI (14): 41.74 | Market Cap: 31.07M | Short Interest: 0.26M | Sales Surprise: - |
+---------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.09 | Shs Outstand: 36.55M | Beta: 1.20 | EPS Surprise: -9.09% |
+---------------------+-----------------------+------------------------+----------------------+
| SMA20: -8.77% | Shs Float: 34.97M | Sales Q/Q: - | P/E: - |
+---------------------+-----------------------+------------------------+----------------------+
| SMA50: -16.27% | Inst Own: 2.77% | Sales past 5Y: 0.00% | Earnings: Apr 03 BMO |
+---------------------+-----------------------+------------------------+----------------------+
| SMA200: -24.52% | Insider Own: 4.13% | Employees: 10 | |
+---------------------+-----------------------+------------------------+----------------------+
| Perf Week: 7.59% | Insider Trans: 8.69% | Debt/Eq: 0.06 | |
+---------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading by RenovoRx officers or majority shareholders (if available).

Inside Trans: RenovoRx, Inc. (RNXT) by Agah Ramtin (Chief Medical Officer) on 2025-04-11
- Common Stock: 20000 shares at $0.8 (D)

Inside Trans: RenovoRx, Inc. (RNXT) by Bagai Shaun (Chief Executive Officer) on 2025-04-09
- Common Stock: 10000 shares at $0.83 (D)

Inside Trans: RenovoRx, Inc. (RNXT) by Agah Ramtin (Chief Medical Officer) on 2025-04-09
- Common Stock: 30000 shares at $0.8133 (D)

Inside Trans: RenovoRx, Inc. (RNXT) by Kocak Ron (VP Controller and PAO) on 2025-04-08
- Common Stock: 95 shares at $0.8 (D)
- Common Stock: 6000 shares at $0.8 (D)
- Common Stock: 6500 shares at $0.79 (D)

Inside Trans: RenovoRx, Inc. (RNXT) by Agah Ramtin (Chief Medical Officer) on 2025-04-08
- Common Stock: 26000 shares at $0.84 (D)

Inside Trans: RenovoRx, Inc. (RNXT) by Marton Laurence (Unknown Title) on 2025-04-08
- Common Stock: 12050 shares at $0.848 (D)

Inside Trans: RenovoRx, Inc. (RNXT) by Bagai Shaun (Chief Executive Officer) on 2025-04-07
- Common Stock: 10000 shares at $0.83 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -9163000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.8448
Average Volume: 102252.9
30-Day High: 1.07
30-Day Low: 0.772

[Detailed Financials: Q3 2024]
- Total Assets: $10,031,000.0
- Total Liabilities: $2,960,000.0
- Total Equity: $7,071,000.0
- Current Assets: $10,031,000.0
- Current Liabilities: $1,772,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $12,004,000.0
- Total Liabilities: $2,732,000.0
- Total Equity: $9,272,000.0
- Current Assets: $12,004,000.0
- Current Liabilities: $1,311,000.0

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of RenovoRx (RNXT).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about RenovoRx.

2) MARKET_SCORE[]
This conversation was initiated because RNXT is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for RNXT.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, RNXT could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect RNXT to increase 50% from its current price of $0.84, say: PRICE_TARGET[1.27]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of RenovoRx.

11) ETHICAL_RATING[]
Rate RenovoRx’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

Return only: FIELD[value] for each of the above 11 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

RNXT_IN_29 [2025-04-14 16:06:34 -0400] 126 Bytes | 29 tokens | Cum: 6447 tkns (80.59% of 8k)
==========================================================================

====================================
[2025-04-14 16:06:34] # Analysis Completed
Elapsed Time: 33.13 seconds